Oxular

Oxular Limited, based in Oxford, United Kingdom, is a clinical-stage biotechnology company focused on developing innovative drug-device combination treatments for retinal diseases.

Founded in 2014 by Tom Cavanagh and Ronald K. Yamamoto, Oxular aims to improve the treatment of sight-threatening conditions by providing safe and effective therapeutics that require less frequent dosing. The company specializes in a proprietary drug delivery technology that utilizes a minimally invasive suprachoroidal microcatheter device, known as Oxulumis. This device allows for precise drug administration to the posterior eye, enhancing therapeutic effectiveness while minimizing side effects. Oxular's lead candidate, OXU-001, is designed for the treatment of Diabetic Macular Edema and has received Investigational New Drug clearance from the FDA. The company is also advancing clinical trials for various retinal diseases, including Diabetic Retinopathy and Age-Related Macular Degeneration. In January 2025, Oxular was acquired by Regeneron Pharmaceuticals, expanding its capabilities in the retinal therapeutics market.